Figure 6
Differential iMethyl-liquid between pretreatment and EDT in association with clinical responses. (a) Differential beta values between matched pretreatment and EDT iMethyl-liquid in our lung cancer samples (20 responders and 20 non-responders) at P2, P3, P8, and P9 probes for pretreatment versus 3 weeks after initiating treatment (left) and for pretreatment versus 6 weeks after initiating treatment (right). The differences between non-responder and responder samples for each probe were compared by the Wilcoxon signed-rank test. (b) Differential average methylation value of the 4 probes compared between pretreatment and EDT per sample for the non-responders (left) and responder samples (right). Samples were ordered according to the differential methylation level within each time group. Horizontal dotted lines indicate the mean of the differential methylation levels for each time group. (c) Measurement of pretreatment and EDT performance in predicting ICB responses by ROC-AUC. (d) Average methylation value of all 10 probes compared between the responders and non-responders at the baseline point (left), 3 weeks after initiation of ICB (middle), and 6 weeks after initiation of ICB (right).
